Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
4 NC counties are under alert, including Johnston County.
Program
Only on WRAL at 6: WRAL Investigates recording of apparent confession connected to Fayetteville double-murder case
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
3.740
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
February 15, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Top CRISPR Stocks
February 11, 2023
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
Via
Talk Markets
3 No-Brainer Stocks to Buy Right Now for Less Than $25
February 04, 2023
All three healthcare stocks are showing solid long-term potential.
Via
The Motley Fool
Why Editas Medicine's Shares Jumped This Week
February 03, 2023
The gene-editing biotech's shares have had a strong two-week run.
Via
The Motley Fool
Is Editas Medicine Stock a Buy Now?
February 03, 2023
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
Via
The Motley Fool
Why Editas Medicine Stock Charged Higher in January
February 02, 2023
The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.
Via
The Motley Fool
Expert Ratings for Editas Medicine
February 01, 2023
Via
Benzinga
Why Shares of Editas Medicine Jumped This Week
January 26, 2023
It's been a seesaw month for the clinical-stage gene-editing biotech.
Via
The Motley Fool
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
January 19, 2023
Via
Benzinga
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
February 02, 2023
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.
Via
InvestorPlace
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
February 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
February 01, 2023
Via
Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
Analyst Expectations for Editas Medicine's Future
January 10, 2023
Via
Benzinga
Why Editas Medicine Stock Is Sliding Today
January 09, 2023
The gene-editing pioneer announced a big shake-up with its research and development programs.
Via
The Motley Fool
Analyst Ratings for Editas Medicine
December 06, 2022
Via
Benzinga
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
January 25, 2023
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Via
MarketBeat
Topics
Workforce
Exposures
Layoff
Product Safety
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
January 19, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
January 18, 2023
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years.
Via
InvestorPlace
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
January 09, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Why Shares of Editas Medicine Dropped 15.5% in November
December 05, 2022
The biotech's shares plummeted after it paused a key clinical trial.
Via
The Motley Fool
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
-Clinical Data Due Next Week at ASH-
Via
Benzinga
2 Beaten-Down Stocks to Watch Closely Next Year
December 06, 2022
These biotechs could skyrocket in 2023, but only if they can execute their plans.
Via
The Motley Fool
Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients
December 06, 2022
Via
Benzinga
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
December 06, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
December 01, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Where Will Editas Medicine Be in 1 Year?
November 20, 2022
The company could continue lagging the market for a while.
Via
The Motley Fool
Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
November 18, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
November 18, 2022
Upgrades
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.